Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy (original) (raw)
Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial
Guntram Schernthaner
Journal of the American Society of Nephrology, 2005
View PDFchevron_right
Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations
jack tindall
View PDFchevron_right
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
william clarke
New England Journal of Medicine, 2001
View PDFchevron_right
patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in of Renin-Angiotensin-Aldosterone System Additional services and information for
Antonino Saitta
Journal of Renin-Angiotensin-Aldosterone System
View PDFchevron_right
The New England Journal of Medicine RENOPROTECTIVE EFFECT OF THE ANGIOTENSIN-RECEPTOR ANTAGONIST IRBESARTAN IN PATIENTS WITH NEPHROPATHY DUE TO TYPE 2 DIABETES
Aloysius Sebastian Prayogi
View PDFchevron_right
Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy
Rama Walia
The Indian Journal of Medical Research
View PDFchevron_right
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points
Kasper Rossing
Seminars in Nephrology, 2004
View PDFchevron_right
Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
Kasper Rossing
Annals of Pharmacotherapy, 2004
View PDFchevron_right
Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial
Eduardo Gutierrez
American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013
View PDFchevron_right
The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics
Robert Atkins
Nephrology Dialysis Transplantation, 2000
View PDFchevron_right
Blockade of the renin–angiotensin system for the primary prevention of diabetic nephropathy
Robert Macginley
Diabetes management, 2012
View PDFchevron_right
Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria
Antonino Saitta
Journal of the Renin-Angiotensin-Aldosterone System, 2014
View PDFchevron_right
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy
Kasper Rossing
Kidney International, 2003
View PDFchevron_right
Blood Pressure, Hypertension, RAAS Blockade, and Drug Therapy in Diabetic Kidney Disease
Hala Yamout, George Bakris
Advances in Chronic Kidney Disease, 2014
View PDFchevron_right
Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients
Marc Bouroudian
Journal of Hypertension, 1998
View PDFchevron_right
Combination Therapy of Angiotensin Converting Enzyme Inhibitor and Angiotensin AT1 Receptor Antagonist in Diabetic Nephropathy
Todd MacLaughlan
Hong Kong Journal of Nephrology, 2007
View PDFchevron_right
Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure
David Packham
Nephrology Dialysis Transplantation, 2004
View PDFchevron_right
Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes
E. Frandsen
Kidney International, 2008
View PDFchevron_right
Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria
Frederik Persson
Diabetes Care, 2009
View PDFchevron_right
Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study)
Charlotte Strandhave
PLOS ONE, 2015
View PDFchevron_right
The Effect of Direct Renin Inhibition Alone and in Combination With ACE Inhibition on Endothelial Function, Arterial Stiffness, and Renal Function in Type 1 Diabetes
Vesta Lai, Ronnie Har
Diabetes Care, 2012
View PDFchevron_right
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials
David Packham
European Heart Journal, 2011
View PDFchevron_right
Progression of renal disease--can we forget about inhibition of the renin-angiotensin system? Authors' reply
Johannes Mann
Nephrology Dialysis Transplantation, 2006
View PDFchevron_right
Blockade of the renin-angiotensin system for the primary prevention of diabetic
Robert Macginley
2012
View PDFchevron_right
Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction
Gunter Wolf
Kidney International, 2005
View PDFchevron_right
Dual Blockade of the Renin-Angiotensin System: The Ultimate Treatment for Renal Protection?
I. Codreanu
Journal of the American Society of Nephrology, 2005
View PDFchevron_right
Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial
William Keane
Journal of the American Society of Nephrology, 2007
View PDFchevron_right
RAAS Blockade as First-Line Antihypertensive Therapy among People with CKD
Pantelis Zebekakis
Renin-Angiotensin System - Past, Present and Future, 2017
View PDFchevron_right